Shares of Becton Dickinson & Co. BDX advanced 1.05% to $204.45 Thursday, on what proved to be an all-around positive trading ...

Shares of Becton Dickinson & Co. BDX rose 1.22% to $202.32 Wednesday, on what proved to be an all-around favorable trading ...

Becton, Dickinson and Company (BD) has received the US Food and Drug Administration’s (FDA) 510(k) clearance for the Phasix ...

Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $260.00.

4 analysts have expressed a variety of opinions on Becton Dickinson BDX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced 510(k) clearance ...

Valued at a market cap of $57.1 billion, Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory ...

Valued at a market cap of $57.1 billion, Becton, Dickinson and Company (BDX) is a global medical technology company that ...

MANILA — The US-ASEAN Business Council (USABC) reaffirmed its commitment to building sustainable, inclusive, and people-centered healthcare systems in Southeast Asia by convening a high-level panel ...

With the recent acquisition of Advanced Patient Monitoring, BD continues to advance its collaboration with clinicians to ...